PT Perspective Therapeutics, Inc. Stock: price and management transactions · United States · SEC (Form 4)Source id SEC:perspective-therapeutics-inc-1cf74f US · SEC (Form 4) Mcap US$342.1M Follow the Perspective Therapeutics, Inc. share price and the full management transaction log of the company, a listed issuer based in United States. Shares trade on the US market, under the supervision of SEC (Form 4). Market capitalisation: €342.1m. The latest transaction was disclosed on 4 September 2026 (Cession). Among the most active insiders: Williamson Robert F III. The full history is openly available.
€517,239
4 ops.
Sell Volume
Analyst consensus: bullish or bearish? Analysts rate Perspective Therapeutics, Inc. Strong Buy (bullish), based on 14 analysts. Average price target: US$12.79.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 4 September 2026
All Executives34 Thresholds0 Prospectus0 Other0
Declarations 34 total
▼ 10% Owner · Executives · 31 Aug 2026
78,145 shares @ US$3.143 Common Stock SEC:0002064832-26-000314:0
▼ 10% Owner · Executives · 1 Sept 2026
35,769 shares @ US$3.1193 Common Stock SEC:0002064832-26-000314:1
▼ 10% Owner · Executives · 2 Sept 2026
42,129 shares @ US$3.1147 Common Stock SEC:0002064832-26-000316:0
▼ 10% Owner · Executives · 1 Sept 2026
35,769 shares @ US$3.1193 Common Stock SEC:0002064832-26-000310:0
▲ Chief Accounting Officer · Executives · 13 Nov 2025
11,000 shares @ US$2.0268 23.0% of flow Common Stock SEC:0001193125-25-283953:0
Canonical exit: 11 Feb 2026 (T+90) ▲ Director · Executives · 12 Nov 2025
9,498 shares @ US$2.10 8.8% of flow Common Stock SEC:0001193125-25-281626:0
Canonical exit: 10 Feb 2026 (T+90) ▲ Chief Financial Officer · Executives · 28 Mar 2025
33,333 shares @ US$2.2484 100.0% of flow Common Stock SEC:0000950170-25-048696:0
Canonical exit: 26 Jun 2025 (T+90) ▲ Director · Executives · 28 Mar 2025
22,192 shares @ US$2.27 26.0% of flow Common Stock SEC:0000950170-25-048698:0
Canonical exit: 26 Jun 2025 (T+90) ▲ Director · Executives · 31 Mar 2025
23,475 shares @ US$2.1299 19.6% of flow Common Stock SEC:0000950170-25-048691:0
Canonical exit: 29 Jun 2025 (T+90) ▲ Chief Executive Officer · Executives · 28 Mar 2025
22,026 shares @ US$2.2421 19.4% of flow Common Stock SEC:0000950170-25-048775:0
Canonical exit: 26 Jun 2025 (T+90) ▲ Director · Executives · 4 Dec 2024
25,975 shares @ US$3.85 100.0% of flow Common Stock SEC:0000950170-24-134067:0
Canonical exit: 4 Mar 2025 (T+90) ▲ CEO · Executives · 4 Dec 2024
8,000 shares @ US$3.7665 12.1% of flow Common Stock SEC:0000950170-24-133355:0
Canonical exit: 4 Mar 2025 (T+90) ▲ Director · Executives · 25 Nov 2024
3,647 shares @ US$3.6199 7.0% of flow Common Stock SEC:0000950170-24-131251:0
Canonical exit: 23 Feb 2025 (T+90) ▲ Chief Financial Officer · Executives · 25 Nov 2024
400 shares @ US$3.55 2.1% of flow Common Stock SEC:0000950170-24-131250:0
Canonical exit: 23 Feb 2025 (T+90) ▲ CEO · Executives · 25 Nov 2024
14,500 shares @ US$3.784 22.2% of flow Common Stock SEC:0000950170-24-130754:0
Canonical exit: 23 Feb 2025 (T+90) ▲ Chief Financial Officer · Executives · 17 Jun 2024
1,800 shares @ US$9.815 25.6% of flow Common Stock SEC:0000950170-24-074594:0
Canonical exit: 15 Sept 2024 (T+90) ▲ Director · Executives · 14 Jun 2024
4,504 shares @ US$10.90 19.4% of flow Common Stock SEC:0000950170-24-074592:0
Canonical exit: 12 Sept 2024 (T+90) ▲ CEO · Executives · 13 Jun 2024
100,000 shares @ US$1.1743 46.3% of flow Common Stock SEC:0000950170-24-073145:0
Canonical exit: 11 Sept 2024 (T+90) ▲ Director · Executives · 3 Jun 2024
34,246 shares @ US$1.4598 19.4% of flow Common Stock SEC:0000950170-24-068638:0
Canonical exit: 1 Sept 2024 (T+90) ▲ Director · Executives · 31 May 2024
55,000 shares @ US$1.38 39.1% of flow Common Stock SEC:0000950170-24-067945:0
Canonical exit: 29 Aug 2024 (T+90) ▲ Chief Financial Officer · Executives · 31 May 2024
13,006 shares @ US$1.3999 26.1% of flow Common Stock SEC:0000950170-24-067953:0
Canonical exit: 29 Aug 2024 (T+90) ▲ Director · Executives · 29 May 2024
11,375 shares @ US$1.32 7.8% of flow Common Stock SEC:0000950170-24-066557:0
Canonical exit: 27 Aug 2024 (T+90) ◇ VP Finance/Prin Fin&Acct Offic · Executives · 23 Apr 2024
30,000 shares @ US$0.36 100.0% of flow Common stock SEC:0000950170-24-047645:0
60,431,039 shares @ US$0.95 100.0% of flow Common Stock SEC:0000950170-24-028446:0
Canonical exit: 4 Jun 2024 (T+90) ▲ Director · Executives · 30 Jan 2024
18,579 shares @ US$0.71 6.8% of flow Common Stock SEC:0001437749-24-002837:0
Canonical exit: 29 Apr 2024 (T+90) 25 of 34 declarations
Load more (9 remaining) 关于 Perspective Therapeutics, Inc. Perspective Therapeutics, Inc. 是一家专注于开发创新癌症治疗方法的公司。它在 XNAS 市场上市。